ScholarIQanswers from OpenAlex & ORCID
Kumar Prabhash
ResearcherPublications, citations & collaboration network
Kumar Prabhash is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Kumar Prabhash have?
ScholarIQindexed works
Kumar Prabhash has 934 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kumar Prabhash have?
ScholarIQcitation count
Kumar Prabhash has 13,216 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Kumar Prabhash?
ScholarIQh-index
Kumar Prabhash has an h-index of 50 in OpenAlex.
What is the i10-index of Kumar Prabhash?
ScholarIQi10-index
Kumar Prabhash has an i10-index of 242 in OpenAlex.
What is the ORCID of Kumar Prabhash?
ScholarIQorcid
The ORCID for Kumar Prabhash is on the source record.
What is the OpenAlex record for Kumar Prabhash?
ScholarIQopenalex
The OpenAlex for Kumar Prabhash is on the source record.
What are the most-cited papers on Kumar Prabhash?
ScholarIQmost cited works
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer
Vanita Noronha, Vijay Patil, Amit Joshi, Nandini Menon, Anuradha Chougule, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Rajiv Kumar, Sucheta More, Supriya Goud, Nandkumar Kadam, Nilesh Daware, Atanu Bhattacharjee, Srushti Shah, Akanksha Yadav, Vaishakhi Trivedi, Vichitra Behel, Amit Dutt, Shripad Banavali, Kumar Prabhash
Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study
Giorgio V. Scagliotti, Vera Hirsh, Salvatore Siena, David H. Henry, Penella J. Woll, Christian Manegold, Philippe Solal‐Céligny, Gladys Rodriguez, Maciej Krzakowski, Nilesh Mehta, Lara Lipton, José Á. García-Sáenz, José Rodrigues Pereira, Kumar Prabhash, Tudor–Eliade Ciuleanu, Vladimir Kanarev, Huei Wang, Arun Balakumaran, Ira Jacobs
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
Vanita Noronha, Amit Joshi, Vijay Patil, Jaiprakash Agarwal, Sarbani Ghosh Laskar, Ashwini Budrukkar, Vedang Murthy, Tejpal Gupta, Anil D′Cruz, Shripad Banavali, Prathamesh Pai, Pankaj Chaturvedi, Devendra Chaukar, Nikhil Pande, Arun Chandrasekharan, Vikas Talreja, Dilip Harindran Vallathol, Vijayalakshmi Mathrudev, Aparna Manjrekar, Kamesh Maske, Arati Sanjay Bhelekar, Kavita Nawale, Sadhana Kannan, Vikram Gota, Atanu Bhattacharjee, Shubhada Kane, Shashikant Juvekar, Kumar Prabhash
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
Vedang Murthy, Priyamvada Maitre, Sadhana Kannan, Gitanjali Panigrahi, Rahul Krishnatry, Ganesh Bakshi, Gagan Prakash, Mahendra Pal, Santosh Menon, Reena Phurailatpam, Smruti Mokal, Dipika Chaurasiya, Palak Popat, Nilesh Sable, Archi Agarwal, Venkatesh Rangarajan, Amit Joshi, Vanita Noronha, Kumar Prabhash, Umesh Mahantshetty